{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T05:53:55Z","timestamp":1768974835482,"version":"3.49.0"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"30","license":[{"start":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T00:00:00Z","timestamp":1721952000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,26]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that damages multiple organs and systems, including the lungs, kidneys, and heart. The respiratory system is commonly affected by SLE, leading to problems such as pleurisy, pleural effusion, and interstitial lung disease (ILD). In addition, SLE can involve the heart, with pericarditis being the most common manifestation. Notably, pericardial effusion frequently accompanies pericarditis involved by SLE, and aspects such as thickened pericardium (TP) can be challenging to detect early on. There are limited reports on TP and even fewer reports on the treatment of ILD with TP. This study investigates the clinical treatment of SLE complicating ILD and TP and reports on a successful case treated with tofacitinib, offering new strategies for managing such patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>A 35-year-old female patient presented to the hospital with polyarticular swelling and pain that had been ongoing for over 4 years, as well as recurrent chest pain for 2 years that worsened over the course of 1 day.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>The patient was diagnosed with SLE complicating ILD and TP, with hematologic involvement.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Treatment involved the administration of tofacitinib in combination with low-dose methylprednisolone (MP) and mycophenolate mofetil (MMF).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>The patient experienced recurrent chest pain and difficulty in reducing glucocorticoids (GCs), but the patient conditions were improved upon the addition of tofacitinib. The patient has been followed up for 16 months, and the patient MP dosage has been reduced to 6\u2009mg once daily. The patient condition remains stable without recurrence, and the patient quality of life has improved.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>In cases of SLE complicating ILD and TP, when tapering GCs is difficult, treatment with tofacitinib can be effective in achieving remission and maintaining stability.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000039129","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T14:16:09Z","timestamp":1722003369000},"page":"e39129","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["A case report of systemic lupus erythematosus complicating interstitial lung disease and thickened pericardium treated with tofacitinib"],"prefix":"10.1097","volume":"103","author":[{"given":"Xiaoying","family":"Li","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Baise People's Hospital, Baise, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaoye","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Radiology, Baise People's Hospital, Baise, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Baise People's Hospital, Baise, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3284-5417","authenticated-orcid":false,"given":"Chunfeng","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Baise People's Hospital, Jining, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250716","doi-asserted-by":"crossref","first-page":"iv8","DOI":"10.1093\/rheumatology\/kel308","article-title":"Heart involvement in systemic lupus erythematosus, anti-phospholipid syndrome and neonatal lupus.","volume":"45","author":"Tincani","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"R2-20250716","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/resp.12473","article-title":"Pulmonary manifestations in systemic lupus erythematosus: association with disease activity.","volume":"20","author":"Alamoudi","year":"2015","journal-title":"Respirology"},{"key":"R3-20250716","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1055\/s-0034-1371537","article-title":"Pulmonary manifestations of systemic lupus erythematosus.","volume":"35","author":"Mittoo","year":"2014","journal-title":"Semin Respir Crit Care Med"},{"key":"R4-20250716","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s11926-017-0697-x","article-title":"Cardiopulmonary manifestations of collagen vascular diseases.","volume":"19","author":"Jawad","year":"2017","journal-title":"Curr Rheumatol Rep"},{"key":"R5-20250716","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/1529-0131(200103)44:3<735::AID-ANR125>3.0.CO;2-F","article-title":"Updating the American College of Rheumatology preliminary classification criteria for systemic sclerosis: addition of severe nailfold capillaroscopy abnormalities markedly increases the sensitivity for limited scleroderma.","volume":"44","author":"Lonzetti","year":"2001","journal-title":"Arthritis Rheum"},{"key":"R6-20250716","first-page":"h6819","article-title":"Management of interstitial lung disease associated with connective tissue disease.","volume":"352","author":"Mathai","year":"2016","journal-title":"BMJ (Clin Res Ed)"},{"key":"R7-20250716","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1177\/0961203316630818","article-title":"Impact of pulmonary disease on patient-reported outcomes and patient-performed functional testing in systemic lupus erythematosus.","volume":"25","author":"Fidler","year":"2016","journal-title":"Lupus"},{"key":"R8-20250716","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1191\/0961203305lu2200oa","article-title":"Cardiac involvement in systemic lupus erythematosus.","volume":"14","author":"Doria","year":"2005","journal-title":"Lupus"},{"key":"R9-20250716","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","article-title":"Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.","volume":"73","author":"van Vollenhoven","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"R10-20250716","doi-asserted-by":"crossref","first-page":"i70","DOI":"10.1136\/annrheumdis-2011-200595","article-title":"In vitro and in vivo analysis of a JAK inhibitor in rheumatoid arthritis.","volume":"71","author":"Tanaka","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"R11-20250716","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMra1202117","article-title":"JAKs and STATs in immunity, immunodeficiency, and cancer.","volume":"368","author":"O\u2019Shea","year":"2013","journal-title":"N Engl J Med"},{"key":"R12-20250716","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-021-00726-8","article-title":"Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.","volume":"18","author":"Tanaka","year":"2022","journal-title":"Nat Rev Rheumatol"},{"issue":"Suppl 1","key":"R13-20250716","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/rheumatology\/key280","article-title":"The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases?","volume":"58","author":"Tanaka","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R14-20250716","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1093\/rheumatology\/key339","article-title":"Clinical significance of Janus Kinase inhibitor selectivity.","volume":"58","author":"Choy","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"R15-20250716","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.4049\/jimmunol.1901477","article-title":"Translating JAKs to Jakinibs.","volume":"204","author":"Gadina","year":"2020","journal-title":"J Immunol"},{"key":"R16-20250716","doi-asserted-by":"crossref","first-page":"Itc81","DOI":"10.7326\/AITC202006020","article-title":"Systemic lupus erythematosus.","volume":"172","author":"Kiriakidou","year":"2020","journal-title":"Ann Intern Med"},{"key":"R17-20250716","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMra1100359","article-title":"Systemic lupus erythematosus.","volume":"365","author":"Tsokos","year":"2011","journal-title":"N Engl J Med"},{"key":"R18-20250716","first-page":"294","article-title":"Pulmonary manifestations in systemic lupus erythematosus: pleural involvement, acute pneumonitis, chronic interstitial lung disease and diffuse alveolar hemorrhage.","volume":"14","author":"Aguilera-Pickens","year":"2018","journal-title":"Rheumatol Clin"},{"key":"R19-20250716","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/1573397113666170704102444","article-title":"Cardiovascular and pulmonary manifestations of systemic lupus erythematosus.","volume":"13","author":"Tselios","year":"2017","journal-title":"Curr Rheumatol Rev"},{"key":"R20-20250716","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-0039-1685537","article-title":"Pulmonary complications of systemic lupus erythematosus.","volume":"40","author":"Hannah","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"key":"R21-20250716","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/0049-0172(90)90094-V","article-title":"A long-term study of interstitial lung disease in systemic lupus erythematosus.","volume":"20","author":"Weinrib","year":"1990","journal-title":"Semin Arthritis Rheum"},{"key":"R22-20250716","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005382-199203000-00003","article-title":"Pulmonary manifestations of systemic lupus erythematosus.","volume":"7","author":"Wiedemann","year":"1992","journal-title":"J Thorac Imaging"},{"key":"R23-20250716","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/eurheartj\/ehm193","article-title":"Cardiac involvement in systemic inflammatory diseases.","volume":"28","author":"Knockaert","year":"2007","journal-title":"Eur Heart J"},{"key":"R24-20250716","doi-asserted-by":"crossref","first-page":"275","DOI":"10.4065\/74.3.275","article-title":"Cardiac involvement in systemic lupus erythematosus.","volume":"74","author":"Moder","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"R25-20250716","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.autrev.2017.11.009","article-title":"Targeting interferons and their pathways in systemic lupus erythematosus.","volume":"17","author":"Chasset","year":"2018","journal-title":"Autoimmun Rev"},{"key":"R26-20250716","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/13543784.2019.1551358","article-title":"The Jakinibs in systemic lupus erythematosus: progress and prospects.","volume":"28","author":"Mok","year":"2019","journal-title":"Expert Opin Investig Drugs"},{"key":"R27-20250716","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/art.39818","article-title":"Tofacitinib ameliorates murine lupus and its associated vascular dysfunction.","volume":"69","author":"Furumoto","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R28-20250716","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","article-title":"Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus.","volume":"12","author":"Hasni","year":"2021","journal-title":"Nat Commun"},{"key":"R29-20250716","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease.","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"R30-20250716","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis.","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology (Oxford)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039129","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T23:01:53Z","timestamp":1752706913000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,26]]},"references-count":30,"journal-issue":{"issue":"30","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000039129","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,26]]}}}